Several other equities analysts also recently commented on BTG. J P Morgan Chase & Co reiterated a neutral rating and issued a GBX 790 ($10.29) price objective on shares of BTG plc in a report on Tuesday, March 28th. Numis Securities Ltd reiterated a buy rating and issued a GBX 900 ($11.72) price objective on shares of BTG plc in a report on Wednesday, June 14th. Panmure Gordon reiterated a buy rating and issued a GBX 737 ($9.60) price objective on shares of BTG plc in a report on Thursday, April 20th. Investec reiterated a buy rating and issued a GBX 720 ($9.38) price objective on shares of BTG plc in a report on Thursday, April 6th. Finally, Stifel Nicolaus restated a buy rating and issued a GBX 725 ($9.44) price target on shares of BTG plc in a research note on Tuesday, April 4th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. BTG plc has an average rating of Buy and a consensus price target of GBX 766.44 ($9.98).
Shares of BTG plc (LON BTG) opened at 653.50 on Thursday. The firm’s market capitalization is GBX 2.52 billion. BTG plc has a 52-week low of GBX 528.36 and a 52-week high of GBX 738.50. The firm has a 50-day moving average of GBX 674.66 and a 200 day moving average of GBX 629.49.
TRADEMARK VIOLATION WARNING: “BTG plc (BTG) Receives “not rated” Rating from Shore Capital” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/btg-plc-btg-receives-not-rated-rating-from-shore-capital-updated-updated-updated/1198318.html.
In related news, insider Rolf Soderstrom sold 22,624 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of GBX 649 ($8.45), for a total value of £146,829.76 ($191,209.48).
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.